279 related articles for article (PubMed ID: 31536685)
1. Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma.
Willemsen ACH; Hoeben A; Lalisang RI; Van Helvoort A; Wesseling FWR; Hoebers F; Baijens LWJ; Schols AMWJ
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):145-159. PubMed ID: 31536685
[TBL] [Abstract][Full Text] [Related]
2. Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Willemsen ACH; Degens JHRJ; Baijens LWJ; Dingemans AC; Hoeben A; Hoebers FJP; De Ruysscher DKM; Schols AMWJ
Front Nutr; 2020; 7():600612. PubMed ID: 33324671
[No Abstract] [Full Text] [Related]
3. Prediction model for tube feeding dependency during chemoradiotherapy for at least four weeks in head and neck cancer patients: A tool for prophylactic gastrostomy decision making.
Willemsen ACH; Kok A; van Kuijk SMJ; Baijens LWJ; de Bree R; Devriese LA; Hoebers FJP; Lalisang RI; Schols AMWJ; Terhaard CHJ; Hoeben A
Clin Nutr; 2020 Aug; 39(8):2600-2608. PubMed ID: 31839429
[TBL] [Abstract][Full Text] [Related]
4. Tooth extractions prior to chemoradiation or bioradiation are associated with weight loss during treatment for locally advanced oropharyngeal cancer.
Buurman DJM; Willemsen ACH; Speksnijder CM; Baijens LWJ; Hoeben A; Hoebers FJP; Kessler P; Schols AMWJ
Support Care Cancer; 2022 Jun; 30(6):5329-5338. PubMed ID: 35278135
[TBL] [Abstract][Full Text] [Related]
5. Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer.
Willemsen ACH; Kok A; Baijens LWJ; de Boer JP; de Bree R; Devriese LA; Driessen CML; van Herpen CML; Hoebers FJP; Kaanders JHAM; Karsten RT; van Kuijk SMJ; Lalisang RI; Navran A; Pereboom SR; Schols AMWJ; Terhaard CHJ; Hoeben A
Clin Nutr; 2022 Jan; 41(1):177-185. PubMed ID: 34883306
[TBL] [Abstract][Full Text] [Related]
6. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
[TBL] [Abstract][Full Text] [Related]
8. A comparison of concurrent cisplatin versus cetuximab with radiotherapy in locally-advanced head and neck cancer: A bi-institutional analysis.
Stokes WA; Sumner WA; Breggren KL; Rathbun JT; Raben D; McDermott JD; Gan G; Karam SD
Rep Pract Oncol Radiother; 2017; 22(5):389-395. PubMed ID: 28808428
[TBL] [Abstract][Full Text] [Related]
9. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
10. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Hes C; Desilets A; Tonneau M; El Ouarzadi O; De Figueiredo Sousa M; Bahig H; Filion É; Nguyen-Tan PF; Christopoulos A; Benlaïfaoui M; Derosa L; Alves Costa Silva C; Ponce M; Malo J; Belkad W; Charpentier D; Aubin F; Hamilou Z; Jamal R; Messaoudene M; Soulières D; Routy B
Oral Oncol; 2024 Jan; 148():106623. PubMed ID: 38006691
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
14. Reirradiation for patients with recurrence head and neck squamous cell carcinoma: a single-institution comparative study.
Rudžianskas V; Inčiūra A; Vaitkus S; Padervinskis E; Rudžianskienė M; Kupčinskaitė-Noreikienė R; Saltonaitė L; Noreika A; Statnickaitė A; Juozaitytė E
Medicina (Kaunas); 2014; 50(2):92-9. PubMed ID: 25172603
[TBL] [Abstract][Full Text] [Related]
15. Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).
Furqan M; Snyders TP; Saqlain MU; Mott SL; Laux D; Snow A; Anderson CM; Watkins JM; Clamon GH
Cancer Med; 2019 Jun; 8(6):2730-2739. PubMed ID: 30968604
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
17. Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan.
Kapała A; Surwiłło-Snarska A; Jodkiewicz M; Kawecki A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34064057
[TBL] [Abstract][Full Text] [Related]
18. Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation.
Naumann P; Eberlein J; Farnia B; Liermann J; Hackert T; Debus J; Combs SE
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717736
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
20. Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma.
Grossberg AJ; Chamchod S; Fuller CD; Mohamed AS; Heukelom J; Eichelberger H; Kantor ME; Hutcheson KA; Gunn GB; Garden AS; Frank S; Phan J; Beadle B; Skinner HD; Morrison WH; Rosenthal DI
JAMA Oncol; 2016 Jun; 2(6):782-9. PubMed ID: 26891703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
